InvestorsHub Logo
Followers 62
Posts 7554
Boards Moderated 1
Alias Born 01/02/2003

Re: JRoon71 post# 397286

Monday, 01/09/2023 11:56:23 AM

Monday, January 09, 2023 11:56:23 AM

Post# of 426359
Patent infringement in U.S. is Amarin's main problem...Amarin needs to deal with this, either in the courts(as in the Healthnet case)...or by seeking new patents and FDA approval for MND-2119 plus a FDC product with MND-2119 and statin.

I will be listening to the JPM conference for more information on these themes...I will also be listening for any future prospects for an authorized generic Vascepa.

The science behind Vascepa is solid...Amarin needs more help in the legal and marketing areas.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News